Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer (MODEL-ABC)
Refractory colorectal cancer patient-derived MicroOrganoSpheres (MOS)TM enables correlation of targeted therapy combination response with clinical outcomes
A functional immuno-oncology (IO) assay to assess patient response to immunotherapeutics in metastatic disease
MicroOrganoSpheres as a Clinically Applicable Precision Oncology Platform for the Discovery of Novel Therapies in Colorectal Cancer
Patient-derived MicroOrganoSpheres (MOS)TM enable precision clinical decision-making for multiple myeloma patients
Refractory colorectal cancer patient derived MicroOrganoSpheres (MOS)TM enables correlation of targeted therapy combination response with clinical outcomes